Italian Life Sciences Database

News in the Life Sciences Industry
Results 101 - 120 out of 149 displayed.
« 1 2 3 4 5 6 7 8 »

Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination trial with AM833 and semaglutide in obesity

By: GlobenewsWire - 18 Jun 2020

RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S DISEASE

By: GlobenewsWire - 17 Jun 2020

Sanofi’s investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease

By: GlobenewsWire - 16 Jun 2020

Sanofi invests to make France its world class center of excellence in vaccine research and production

By: GlobenewsWire - 16 Jun 2020

Medit Celebrates 20th Anniversary and Appoints GB (Gyu Bum) Ko as New CEO to Accelerate Growth Strategy

SEOUL, South Korea, June 16, 2020 /PRNewswire/ -- Medit announces the nomination of its new Chief Executive Officer, GB (Gyu Bum) Ko, amidst the company's 20(th) year as a global provider of 3D scanning solutions. Ko joins Medit to accelerate its growth strategy as a leader in the dental... Read more ››

By: PR Newswire Association LLC. - 16 Jun 2020

Novo Nordisk A/S – Share repurchase programme

By: GlobenewsWire - 15 Jun 2020

First Presentations of Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara® at Week 16 in Adults with Moderate-to-Severe Plaque Psoriasis

BRUSSELS, June 12, 2020 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the first presentations of data from the Phase 3 clinical development program of bimekizumab, its investigational IL-17A and IL-17F inhibitor, as part of a virtual session for the American Academy... Read more ››

By: PR Newswire Association LLC. - 12 Jun 2020

Semaglutide 2.4 mg shows superior weight loss versus placebo in the phase 3 trials STEP 2 and STEP 3, thereby successfully completing the programme

By: GlobenewsWire - 12 Jun 2020

Sanofi to present growth opportunities and development strategy for Dupixent® (dupilumab) in type 2 inflammatory diseases

By: GlobenewsWire - 11 Jun 2020

Innovent and Roche Enter into A Strategic Collaboration to Discover and Develop Multiple Products including Cellular Therapies and Bispecific Antibodies

SUZHOU, China, June 8, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced... Read more ››

By: PR Newswire Association LLC. - 09 Jun 2020

Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma

By: GlobenewsWire - 02 Jun 2020

Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time

By: GlobenewsWire - 29 May 2020

« 1 2 3 4 5 6 7 8 »

Looking for companies outside of Italy?

Browse our global Life Sciences lead sourcing platform Biotechgate for company information, product pipelines, licensing opportunities, management details and much more.

Partners

Upcoming Life Sciences Events

November 2020
- Precision in Clinical Trials Summit San Francisco
- Precision in Drug Discovery & Preclinical Summit
- Precision in Medical Devices Summit San Francisco

See Events »

Add an Event »

Latest company news

Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira® in Moderate-to-Severe Psoriasis Patients
31 Oct 2020 (PR Newswire Association LLC.)

Novo Nordisk's operating profit increased by 6% in Danish kroner and by 7% at constant exchange rates (CER) in the first nine months of 2020
30 Oct 2020 (GlobenewsWire)

RECORDATI: PROFIT GROWTH IN THE FIRST NINE MONTHS OF 2020. REVENUES -0.6%, EBITDA +7.1%, ADJUSTED NET INCOME +12.3%
29 Oct 2020 (GlobenewsWire)

News in the Life Sciences Industry

Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination trial with AM833 and semaglutide in obesity

RECORDATI: ISTURISA® (OSILODROSTAT) PHASE III LINC-4 TRIAL MEETS ITS PRIMARY ENDPOINT IN CUSHING’S DISEASE

Sanofi’s investigational enzyme replacement therapy shows clinically meaningful improvement in critical manifestations of late-onset Pompe disease

Sanofi invests to make France its world class center of excellence in vaccine research and production

Medit Celebrates 20th Anniversary and Appoints GB (Gyu Bum) Ko as New CEO to Accelerate Growth Strategy

Novo Nordisk A/S – Share repurchase programme

First Presentations of Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara® at Week 16 in Adults with Moderate-to-Severe Plaque Psoriasis

Semaglutide 2.4 mg shows superior weight loss versus placebo in the phase 3 trials STEP 2 and STEP 3, thereby successfully completing the programme

Sanofi to present growth opportunities and development strategy for Dupixent® (dupilumab) in type 2 inflammatory diseases

Innovent and Roche Enter into A Strategic Collaboration to Discover and Develop Multiple Products including Cellular Therapies and Bispecific Antibodies

Sanofi to present Phase 3 results of avalglucosidase alfa in patients with late-onset Pompe disease

Novo Nordisk reports weight loss of 14.9% (16.9% if taken as intended) in STEP 1 trial

Novo Nordisk A/S – Share repurchase programme

Sanofi to launch “Action 2020”, a worldwide employee stock purchase plan

European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma

Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma

Sanofi to present oncology strategy, provide update on portfolio and emerging pipeline

SI-BONE, Inc. Announces $40 Million Debt Re-Financing

Sanofi announces closing of Regeneron stock sale

Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time

Looking for companies outside of Italy?

Partners

Upcoming Life Sciences Events

Latest company news